Jack Anders Net Worth

The estimated Net Worth of Jack Anders is at least $4.51 Millón dollars as of 17 June 2024. Mr Anders owns over 1,893 units of Revolution Medicines Inc stock worth over $4,214,992 and over the last 5 years he sold RVMD stock worth over $295,228.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Anders RVMD stock SEC Form 4 insiders trading

Mr has made over 18 trades of the Revolution Medicines Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,893 units of RVMD stock worth $70,779 on 17 June 2024.

The largest trade he's ever made was exercising 24,524 units of Revolution Medicines Inc stock on 23 October 2023 worth over $73,082. On average, Mr trades about 3,540 units every 56 days since 2020. As of 17 June 2024 he still owns at least 101,176 units of Revolution Medicines Inc stock.

You can see the complete history of Mr Anders stock trades at the bottom of the page.

Mr. Jack Anders biography

Jack Anders is the Sr. VP of Fin. & Principal Accounting Officer at Revolution Medicines Inc.

How old is Mr Anders?

Mr Anders is 44, he's been the Sr. VP of Fin. & Principal Accounting Officer of Revolution Medicines Inc since . There are 14 older and 3 younger executives at Revolution Medicines Inc. The oldest executive at Revolution Medicines Inc is Elizabeth Anderson, 62, who is the Independent Director.

What's Mr Anders's mailing address?

Jack's mailing address filed with the SEC is C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY, CA, 94063.

Insiders trading at Revolution Medicines Inc

Over the last 5 years, insiders at Revolution Medicines Inc have traded over $249,645,422 worth of Revolution Medicines Inc stock and bought 3,371,315 units worth $74,500,278 . The most active insiders traders include Peter Svennilson, Thilo Schroeder y Rock Ventures Ii, L.P.Third.... On average, Revolution Medicines Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,075,216. The most recent stock trade was executed by Stephen Michael Kelsey on 13 August 2024, trading 16,667 units of RVMD stock currently worth $68,168.

What does Revolution Medicines Inc do?

revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.

Complete history of Mr Anders stock trades at Revolution Medicines Inc

Revolution Medicines Inc executives and stock owners

Revolution Medicines Inc executives and other stock owners filed with the SEC include:

• Mark Goldsmith,
  Chairman of the Board, President, Chief Executive Officer
• Margaret Horn,
  Chief Operating Officer, General Counsel
• Steve Kelsey,
  President of Research and Development
• Dr. Mark A. Goldsmith Ph.D.,
  CEO, Pres & Chairman
• Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.,
  Pres of R&D
• Margaret A. Horn J.D.,
  COO, Gen. Counsel & Sec.
• Dr. Stephen M. Kelsey M.D., FRCP, FRC Path.,
  Pres of R&D
• Margaret A. Horn,
  COO, Gen. Counsel & Sec.
• Xiaolin Wang,
  Exec. VP of Clinical Devel.
• Dr. Mark A. Goldsmith M.D., Ph.D.,
  CEO, Pres & Chairman
• Alexis Borisy,
  Lead Independent Director
• Barbara Weber,
  Independent Director
• Vincent Miller,
  Independent Director
• Elizabeth Anderson,
  Independent Director
• Peter Svennilson,
  Independent Director
• Thilo Schroeder,
  Independent Director
• Eric Schmidt,
  Independent Director
• Neil Exter,
  Independent Director
• Jack Anders,
  Vice President - Finance and Principal Accounting Officer
• Dr. Martin D. Burke M.D., Ph.D.,
  Co-Founder & Chairman of Scientific Advisory Board
• Jack Anders,
  Sr. VP of Fin. & Principal Accounting Officer
• Luan M. Wilfong,
  Sr. VP of HR
• Walter Reiher Ph.D.,
  Chief Information Officer
• David L. Pompliano,
  Founding Chief Scientific Officer
• Dr. Kevan M. Shokat,
  Academic Co-Founder & Member of Scientific Advisory Board
• Dr. Michael A. Fischbach,
  Academic Co-Founder & Member of Scientific Advisory Board
• Dr. Martin D. Burke,
  Co-Founder & Chairman of Scientific Advisory Board
• Frank Clyburn,
  
• Group Iii, Lpcolumn Group I...,
  
• Laurence Lasky,
  Director
• Group Iii, Lp Svennilson Pe...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Rock Ventures Iv, L.P.Third...,
  
• James E Deerfield Mgmt Iv, ...,
  
• Lin Wei,
  Chief Medical Officer
• Jeff Cislini,
  General Counsel
• Stephen Michael Kelsey,
  See Remarks
• Rock Ventures Iii, L.P.Thir...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Xiaolin Wang,
  See Remarks
• Rock Ventures Ii, L.P.Third...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Sushil Patel,
  
• Flavia Borellini,
  
• Lorence H. Kim,